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germ cell tumours
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Testicular Tumour Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK.
Summary Renal function was determined before and at varying times after chemotherapy in 62 patients with
metastatic germ cell tumours treated with carboplatin. Eighteen patients were excluded because of urinary
tract obstruction, leaving 44 evaluable patients treated with carboplatin either as a single agent (13 patients) or
in combination with other agents (31 patients). No significant differences were observed in mean"Cr-labelled
Ethylenediamine tetraacetic acid (EDTA) clearances before and after carboplatin in either the group as a
whole (P = 0.58), or when assessment at 1 month or less (P = 0.4), 3 months or less (P = 0.91), or later than
3 months (P = 0.38) were analysed. Carboplatin does not have significant renal toxicity when used at
conventional dosage in patients with germ cell tumours.
The nephrotoxicity of cisplatin in the treatment of various
malignancies, including testicular germ cell tumours, is well
documented (Dentino et al., 1978; Meijer et al., 1983; Groth
et al., 1986; Hansen et al., 1988; Barton et al., 1988; Hamil-
ton et al., 1989). With the introduction of the cisplatin
analogue carboplatin it was hoped that an equally effective
treatment might be available without the attendant nephro-
toxicity, obviating the hospitalisation, intensive hydration
and forced diuresis needed for cisplatin therapy (Calvert et
al., 1985).
A recent study of 10 patients with lung cancer treated with
carboplatin and vincristine at conventional doses showed a
median fall in glomerular filtration rate (GFR) of 19% post
treatment (Sleijfer et al., 1989), suggesting that the perceived
benefits of carboplatin in terms of nephrotoxicity might not
be as great as initially reported. In the treatment of meta-
static germ cell tumours the possibility of long-term side
effects is especially important since the patient population
comprises young adults who have usually been cured of their
disease. We therefore evaluated glomerular filtration rate in
patients undergoing carboplatin-containing chemotherapy for
metastatic germ cell tumours at the Royal Marsden Hospital
in order to determine the nephrotoxic effects of carboplatin
in this group of patients.
Patients and methods
Sixty-two patients with metastatic germ cell tumours were
treated with either single agent carboplatin (21 patients,
mean age 35.8 years, range 23-58 years) or carboplatin plus
bleomycin and etoposide (CEB; 41 patients, mean age 28
years, range 10-48 years). Eighteen patients had hydro-
nephrosis or evidence of encroachment of disease onto the
urinary tract, and they were excluded from the statistical
analysis irrespective of their change in renal function after
carboplatin, leaving 31 patients treated with CEB and 13
treated with carboplatin who were eligible for analysis.
Patients treated with single agent carboplatin received a dose
of 400 mg m-2 repeated every 3 weeks to a maximum of six
courses, with dose modifications for GFR of <80 or
> 120 ml min-' as described elsewhere (Horwich et al.,
1989). The carboplatin dosage for patients treated with CEB
was calculated on the basis of the EDTA clearance according
to the formula
Dose (mg) = 5 x (GFR + 25)
to result in an area under the serum concentration/time curve
of 5 mgminml-' (Calvert et al., 1985). In all patients the
dose was reviewed after the day 16 full blood count. In
patients with a nadir white cell count above 2,000 mm-2 or a
platelet count above 100,000 mm-3 the dose was increased by
10%. In patients with a nadir white cell count below
1,000 mm 3 or a platelet count below 50,000 mm-3 the dose
was reduced by 10% (Horwich et al., 1991).
Glomerular filtration rate (GFR) was estimated from the
plasma decay curve of 51-Cr-EDTA as previously described
(Chantler et al., 1969), and was not corrected for body
surface area. All patients had their GFR measured before
treatment, and this was repeated between 2 weeks and 26
months following their last injection of carboplatin. The
post-chemotherapy assessment was performed at 1 month or
less in 16 patients, 1-3 months in six patients, and more
than 3 months after the last dose of carboplatin in 22
patients.
Statistical analysis of pre- and post-chemotherapy GFRs
was performed using a paired t-test.
Results
The mean carboplatin doses received by the 44 evaluable
patients were 757.3 mg in those treated with single agent
carboplatin (range 485-950 mg), and 739.4 mg in those
treated with CEB (range 480-1,000mg).
The mean pre-treatment GFR in the 44 evaluable patients
was 124.4mlmin-'. In the group of patients assessed at 1
month or less the mean pre-tratment GFR was 116.3 ml
min-' (range 72-181 ml min-'). When the six patients
assessed at 1-3 months were added to these the mean pre-
treatment GFR was 118.4 ml min-' (range 72-181 ml
min-'). In the group of patients assessed more than 3
months after carboplatin the mean pre-treatment GFR was
130.4 ml min-' (range 87-205 ml min-'). The percentage
change in GFR in the 44 analysed patients is shown in
relation to the timing of their post-chemotherapy assessment
in Figure 1. It is estimated that the individual accuracy for
serial estimations of GFR by this method will be within
10%, and it is apparent that most patients experienced no
significant change or an improvement in renal function fol-
lowing treatment with carboplatin. Using paired t-test
analyses, the mean GFRs post-treatment were not
significantly different from pre-treatment values when post-
chemotherapy assessments were analysed at 1 month or less
(P = 0.4), 3 months or less (P = 0.91), greater than 3 months
(P = 0.38), or when all evaluable patients were considered
(P = 0.58) (Table I).
When the whole group of 62 patients was examined, 13
(21%) were shown to have experienced a fall in GFR of 10%
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Figure 1 Percentage change in GFR in 44 evaluable patients
plotted against the time after chemotherapy at which the assess-
ment was made.
or more, and 19 (31%) experienced an improvement in GFR
of 10% or more following carboplatin. The characteristics of
these patients are shown in Tables II and III. Of the 13
patients with a > 10% fall in GFR, three had a thrombosis
of the inferior vena cava prior to treatment, one had evidence
of tumour encroachment on the renal vessels, and three had
a large retroperitoneal mass which increased in size after
chemotherapy due to cystic enlargement of a differentiating
teratomatous deposit in two cases, and relapse just prior to
the GFR estimation in the third. Any of these factors might
have contributed to the deterioration in renal function. No
contributory factors could be identified in six patients. Of the
19 patients with a > 10% rise in GFR after chemotherapy
six had had hydronephrosis which improved or resolved after
treatment (two patients having had a stent inserted), and
three had evidence of displacement of the renal tract without
hydronephrosis which improved after treatment. It is possible
that resolution of these factors after carboplatin might have
contributed to the improvement seen in GFR. No con-
tributory factors could be identified in ten patients.
Discussion
Given the success of treatment with chemotherapy in meta-
static germ cell tumours, the problem of toxicity is one of
major importance. Carboplatin was developed as a cisplatin
analogue whose spectrum of toxicity differed from the parent
compound in being less nephrotoxic, neurotoxic, and
ototoxic, though more toxic to bone marrow. It is important
to know whether substitution of cisplatin by carboplatin
actually does reduce the renal damage previously reported in
testicular tumour patients (Dentino et al., 1978; Meijer et al.,
1983; Groth et al., 1986; Hansen et al., 1988; Hamilton et al.,
1989). It is also important to know whether carboplatin
might substitute for cisplatin in patients unsuitable for treat-
ment with the latter by virtue of poor renal function.
Sleijfer et al. (1989) reported on renal function in ten
patients with lung cancer treated with carboplatin and vin-
cristine, and suggested that carboplatin caused a significant
fall in GFR that was detectable after the second course of
chemotherapy. The dose of carboplatin was 400 mg m-2,
repeated every 4 weeks to a maximum of five cycles. The age
range of their patients was 48 to 69 years, which is con-
siderably older than the age range in this series of testicular
tumour patients.
In the phase I studies of carboplatin no evidence of
Table I Changes in glomerular filtration rate after carboplatin according to time of assessment
post-chemotherapy
All evaluable Post-carboplatin assessment at;
patients 0-1 month 0-3 months >3 months
Mean GFR 124.4 ml min- 1 16.3 ml min' 118.4 ml min-' 130.4 ml min-
prechemotherapy
Mean GFR post 126.4 ml min-' 120.3 ml min'- 118 ml min-' 134.8 ml min-
chemotherapy
Difference between + 2 ml min-' + 4 ml min-' -0.4 ml min-' + 4.4 ml min-
means
P 0.58 0.4 0.91 0.38
Table II Characteristics of patients with a post-carboplatin fall of 10% or more in glomerular
filtration rate
Patient Histology Stage Hydronephrosis Other % Fall in GFR
AH MTU IVCL3H + + IVC thrombosis 21*
HJ MTI IIIBN + - Large mass post 24*
chemotherapy
JW MTI IVCL2 - Displaced kidney 12*
Large mass post
chemotherapy
DM SEMINOMA IVOLI - - 27
DA SEMINOMA mediastinal - Retroperitoneal node 25*
primary relapse after
chemotherapy
DG SEMINOMA IIIOM + - - 12
CH SEMINOMA IIC - IVC thrombosis 13*
SS SEMINOMA IIIC - Tumour encasing 13*
renal vessels on
both sides
NC TD IIIOM+ - - 10
PG Ovarian dysgerminoma - - 13
positive peritoneal
cytology
DP SEMINOMA IVOL2 - IVC thrombosis 38
TP MTI IIB - - 25
DA MTU IIA - - 10
'Patients with an asterisk were among those excluded from the statistical analysis.
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Table III Characteristics of patients with a post-carboplatin rise of 10% or more in glomerular
filtration rate
Hydronephrosis
Patient improving after
Histology Stage chemotherapy Other % Fall in GFR
KE MTU IIICN + - Displaced ureter 21
resolved after
chemotherapy
CF SEMINOMA IVBLI - - 21
AM MTI IVCL2 + - 31*
MB NO BIOPSY IVCLI + - 46
TS MTU IVBLIN + M + - Large renal hilar 15*
mass, resolved
after chemotherapy
DB SEMINOMA IVBLI - - 35
AC SEMINOMA IIIOM + N + - - 61
IN SEMINOMA IIC + - 62
DB SEMINOMA IIC - Large mass 29*
displacing renal
vessels, improved
after chemotherapy
JP TD IVCL3 + - 10*
SK MTI IIB - - 31
SD SEMINOMA IIC - - 20
SI MTI IIB - - 15
ST SEMINOMA IIIC - - 13
RS SEMINOMA IIC - - 19
JP SEMINOMA primary - - 13
mediastinal
JB SEMINOMA IIICN + + - 47*
BB MTI IIIO - - 30
JB SEMINOMA IIC + - 12*
'Patients with an asterisk were among those excluded from the statistical analysis.
nephrotoxicity attributable to the drug was seen, even in
patients with impaired renal function, at doses ranging
between 150 and 520mgm2 (Egorin et al., 1984; Calvert et
al., 1985). However, in phase I studies of high dose carbo-
platin there is evidence of some reduction in the post treat-
ment GFR (Gore et al., 1987; Shea et al., 1989), although
this may be a transient phenomenon which usually recovers
by 3 months after chemotherapy (Hardy et al., 1990). In this
study using conventional doses of carboplatin we have found
no overall evidence of a similar, early reduction in GFR,
patients being as likely to experience an improvement in their
GFR as they are a decline in the period of up to 1 month
carboplatin (Figure 1, Table I). Carboplatin has been shown
to be nephrotoxic in rats, but only in combination with the
aminoglycoside tobramycin, and not when used alone (Breg-
man & Williams, 1986).
We have found no overall evidence of significant nephro-
toxicity in patients with metastatic germ cell tumours at any
time after treatment with carboplatin. However, of the whole
group of 62 patients (including those patients not analysed
statistically) 21% had a 10% or greater fall in their post
treatment GFR. In half of these patients other significant
contributary factors were present, but there remain a small
number of patients with a decline in their post-chemotherapy
GFR in whom it is difficult to exclude the possibility that the
chemotherapy could have been responsible. It is difficult to
assess the extent to which factors such as the state of hydra-
tion, concomitant alcohol consumption, nausea and vomit-
ing, and intercurrent illness may affect day-to-day variations
in GFR in these patients. Such physiological variations in
GFR could be contributary in those patients shown in Figure
I to have had large percentage changes in post-chemotherapy
GFR, in whom there was no evidence of hydronephrosis or
encroachment on the urinary tract by disease.
On the basis of these results we conclude that carboplatin
is a safe drug to administer without intravenous hydration,
and that it does not cause a significant degree of nephrotoxi-
city in patients with metastatic germ cell tumours.
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